Moxifloxacin Acino (Moxifloxacin Hydrochloride)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that unwind and reseal DNA during replication and transcription. Inhibiting these enzymes prevents bacterial DNA synthesis, leading to cell death. This mechanism gives moxifloxacin a broad‑spectrum, bactericidal effect against many Gram‑positive and Gram‑negative organisms.

The dosage of Moxifloxacin Acino is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and other clinical factors. Healthcare professionals follow local guidelines and product labeling to select the appropriate intravenous dose and treatment duration.

Moxifloxacin is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the drug may pass into breast milk, so a risk‑benefit assessment by the prescriber is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a more favorable dosing schedule for intravenous use, but like all fluoroquinolones, it shares class‑related safety considerations that must be weighed against alternatives.

Moxifloxacin Acino should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves drug stability and potency until the point of administration.

Moxifloxacin Acino is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The infusion rate and duration are set by the prescriber according to the patient’s clinical condition and institutional protocols.

Serious risks include tendon rupture, QT‑interval prolongation leading to potentially fatal arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these events.

Moxifloxacin Acino is contraindicated in patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled arrhythmias, or those taking multiple QT‑prolonging agents without appropriate monitoring.